Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects

British Journal of Clinical Pharmacology

Volumn 43, Issue 2, 1997, Pages 155-161

  Thorsson, L ^a   Dahlstrom K ^a   Edsbacker S ^a   Kallen A ^a   Paulson, J ^a   Wiren J E ^a  

^a ASTRAZENECA R AND D   (Sweden)

Author keywords

Cortisol suppression; Diskhaler ; Fluticasone propionate; Systemic availability

Indexed keywords

FLUTICASONE PROPIONATE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HUMAN; HUMAN EXPERIMENT; HYDROCORTISONE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL;

EID: 0031044945     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1997.d01-1425.x     Document Type: Article

References (27)

1. Harding SM. The human pharmacology of fluricasone propionate. Respiratory Medicine, 1990; 84(suppl A): 25-29.
2. Fabbri L, Burge PS, Croonenborgh L, et al. Comparison of fluticasone propionate with beclomethasone dipropionate in moderate to severe asthma treated for one year. Tliorax 1993; 48: 817-23.
3. O'Shaughnessy KM, Gillies B, Fuller RW. Serum and urinary cortisol levels are unaltered by two weeks of inhaled fluticasone propionate. Am Rev Respir Dis 1993; 147(suppl): A293.
4. Grahnén A, Brundin RM, Ling-Andersson A, Eckernäs S-Å. Suppressive effect on the HPA-axis of therapeutic doses of fluticasone propionate in healthy volunteers. BrJ Clin Phannacol 1994; 38: 521-525.
5. Lindberg C, Blomqvist A, Paulson J. Determination of (22R,S)budesonide in human plasma by automated liquid chromatography/thermospray mass spectrometry. Biol Mass Spectram 1992; 21: 525-533.
6. TDx® endocrine assays - cortisol. Abbott Laboratories, North Chicago, IL 60064, USA. R-108; pp 23.16-42.
7. Davidian M, Giltinan DM. Some general estimation methods for nonlinear mixed-effects models. J Biophann Stat 1993; 3: 23-55.
8. Lönnebo A, Grahnén A, Jansson B, Brundin RM, Ling-Andersson A, Eckernäs S-Å. An assessment of the systemic activity of single and repeated doses of inhaled fluricasone propionate (1000 μg twice daily) and budesonide (800 μg twice daily) in healthy volunteers. EnrJ Clin Phannacol 1996; 49: 459-463.
9. Ryrfeldt A, Andersson P, Edsbäcker S, Tönnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982; 63(Suppl 122): 86-95.
10. Möllman H, Rohdewald P, Schmidt EW, Salomon V, Derendorf H. Pharmacokinetics of triamcinolone acetonide and its phosphate ester. EurJ Clin Phannacol 1985; 29: 85-89.
11. Chaplin MD, Rooks IIW, Swenson EW, Cooper WC, Nerenberg C, Chu NI. Flunisolide metabolism and dynamics of a metabolite. Clin Phannacol Tlier 1980; 27: 402-413.
12. Thorsson L, Edsbäcker S, Conradson T-B. Lung deposition of budesonide from Turbuhaler® is twice that from a pressurized metered-dose inhaler P-MDI. EUT Respir J 1994; 7: 1839-1844.
13. Jenner WN, Kirkham DJ. Immunoassay of beclomethasone 17, 21-dipropionate and metabolites. In Bioanalysis ofdnigs and metabolites, eds Reid E, Robinson JD, Wilson ID: Plenum, 1988; 77-86
14. Rowland M, Tozer TN. In Clinical phannacokinetics: concepts and applications. Third Edition, Philadelphia and London: Williams & Wilkins, 1995.
15. Mackie AE, Ventresca GP, Fuller RW, Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. BrJ Clin Phannacol 1996; 41: 539-542.
16. Fuller R, Johnson M, Bye A. Fluticasone propionate-an update on preclinical and clinical experience. Respir Med 1995; 89(Suppl A): 3-18.
17. Ayres JG, Bateman ED, Lundbäck B, Harris TAJ. High dose fluticasone propionate, 1 mg daily, ν fluricasone propionate, 2 mg daily, or budesonide, 1.6 mg daily, in patients with chronic severe asthma. Eur Respir J 1995; 8: 579-586.
18. Dahl R, Lundbäck B, Malo JL, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest 1993; 104: 1352-1358.
19. Chervinsky P, Van As A, Bronsky EA, et al. Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthma. J Allergy Clin Immimol 1994; 94: 676-683.
20. Clark DJ, Grove A, Cargill RI, Lipworth BJ. Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Tliorax 1996; 51: 262-266.
21. Todd G, Dunlop K, McNaboe J, Ryan MF, Carson D, Shields MD. Growth and adrenal suppression in asthmatic children treated with high-dose fluticasone propionate. Lancet 1996; 348: 27-29.
22. Kaiser H, Edsbacker S. Dose-proportional pharmacokinetics (PK) of inhaled budesonide (Pulmicort® Turbuhaler®) in patients with mild asthma. Am J Respir Crit Care Med 1994; 149: A467.
23. Harter JG, Reddy WJ, Thorn GW. Studies on an intermittent corticosteroid dosage regimen. N Engl J Med 1963; 269: 591-596.
24. Grahnén A, Jansson B, Brundin RM, et al. A dose-response study comparing suppression of plasma cortisol induced by fluticasone propionate from Diskhaler® and budesonide from Turbuhaler®. Enr J Clin Phamiacol (submitted).
25. Ventresca GP, Mackie AE, Moss JA, McDowall JE, Bye A. Absorption of oral fluticasone propionate in healthy subjects. Am J Respir Crit Care Med 1994; 149 (4 pt 2): A214.
26. Biddiscombe M, Marriott RJ, Melchor R, Short MD, Spiro SG, Taylor AJ. The preparation and evaluation of pressurized metered-dose and dry powder inhalers containing 99mTc-labelled salbutamol. J Ae r A led 1991; 4(suppl 1): 9.
27. Melchor R, Biddiscombe MF, Mak VHP, Short MD, Spiro SG. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Tliorax 1993; 48: 506-511.